TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) turned a profit of NT$1.1 billion (US$39.33 million) last quarter following NT$1.29 billion in payments from China’s Zhejiang Medicine Co (浙江醫藥集團) after transferring the patent of an antibacterial drug, the company said on Wednesday.
Following a first-quarter net loss of NT$43.65 million, TaiGen reported net profit of NT$1.05 billion for the first half of this year, with earnings per share of NT$1.47, compared with losses per share of NT$0.24 a year earlier, the company said in a statement.
The Taipei Exchange-listed company has collaborated with Zhejiang Medicine since 2012, authorizing the Chinese firm to manufacture Taigenxyn (nemonoxacin) capsules and sell them for a royalty in China.
In the spring, the two firms revised their collaboration: TaiGen sold the Chinese patent for Taigenxyn to Zhejiang Medicine, which gave TaiGen one-time payments, the company told the Taipei Times by telephone.
The two firms had planned to jointly apply for marketing approval for Taigenxyn administered by intravenous infusion, but Chinese regulations only allow one company to apply, it said.
“After a long discussion, we decided to sell our patent to Zhejiang Medicine so that the Chinese firm could apply for marketing approval,” TaiGen said.
TaiGen would use the NT$1.29 billion in payments to develop a new antibiotic for a drug-resistant bacterium, it said.
Shares of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) came under pressure yesterday after a report that Apple Inc is looking to shift some orders from the Taiwanese company to Intel Corp. TSMC shares fell NT$55, or 2.4 percent, to close at NT$2,235 on the local main board, Taiwan Stock Exchange data showed. Despite the losses, TSMC is expected to continue to benefit from sound fundamentals, as it maintains a lead over its peers in high-end process development, analysts said. “The selling was a knee-jerk reaction to an Intel-Apple report over the weekend,” Mega International Investment Services Corp (兆豐國際投顧) analyst Alex Huang
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is expected to remain Apple Inc’s primary chip manufacturing partner despite reports that Apple could shift some orders to Intel Corp, industry experts said yesterday. The comments came after The Wall Street Journal reported on Friday that Apple and Intel had reached a preliminary agreement following more than a year of negotiations for Intel to manufacture some chips for Apple devices. Taiwan Institute of Economic Research (台灣經濟研究院) economist Arisa Liu (劉佩真) said TSMC’s advanced packaging technologies, including integrated fan-out and chip-on-wafer-on-substrate, remain critical to the performance of Apple’s A-series and M-series chips. She said Intel and Samsung
TRANSITION: With the closure, the company would reorganize its Taiwanese unit to a sales and service-focused model, Bridgestone said Bridgestone Corp yesterday announced it would cease manufacturing operations at its tire plant in Hsinchu County’s Hukou Township (湖口), affecting more than 500 workers. Bridgestone Taiwan Co (台灣普利司通) said in a statement that the decision was based on the Tokyo-based tire maker’s adjustments to its global operational strategy and long-term market development considerations. The Taiwanese unit would be reorganized as part of the closure, effective yesterday, and all related production activities would be concluded, the statement said. Under the plan, Bridgestone would continue to deepen its presence in the Taiwanese market, while transitioning to a sales and service-focused business model, it added. The Hsinchu
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has approved a capital budget of US$31.28 billion for production expansion to meet long-term development needs during the artificial intelligence (AI) boom. The company’s board meeting yesterday approved the capital appropriation plan for purposes such as the installation of advanced technology capacity and fab construction, the world’s largest contract chipmaker said in a statement. At an earnings conference last month, TSMC forecast that its capital expenditure for this year would be at the higher end of the US$52 billion to US$56 billion range it forecast in January in response to robust demand for 5G, AI and
RSS